Sumati V. Gupta,
MD
Languages Spoken: English, Hindi, Marathi
Sumati Gupta, MD, is an Assistant Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute.
Dr. Gupta is a specialist in adult medical oncology and her main areas of interest include Genitourinary Cancer (bladder, kidney, prostate and testicular cancer).
Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. She practiced at the University of Utah Clinics for 10 years in Primary Care and Geriatrics.
Dr. Gupta then completed fellowship in Medical Oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in Internal Medicine and Medical Oncology.
Dr. Gupta is a member of the Genitourinary Cancers program and the Genitourinary Malignancy Disease Oriented Team at the Huntsman Cancer Institute. She is a member of the American Society of Clinical Oncology. Dr. Gupta also does preclinical and clinical research at Huntsman Cancer Institute and her main areas of research interest are Epigenetics, Chemotherapy Resistance, Targeted therapy and Immunotherapy in the treatment of cancer.
Dr. Gupta is a clinical investigator and treats patients on clinical trials at Huntsman Cancer Institute. She also investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.
Dr. Gupta is also involved in individual and population-based studies to identify genetic and environmental risks of bladder cancer.
Dr. Gupta is a member of University of Utah’s Institutional Review Board. She also holds a part- time appointment at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and provides clinical expertise in Genitourinary Cancers.
Clinical Locations
Clinic 2B, GU
801-585-0250
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.5/ 5
Care provider's explanation of condition/problem
4.5/ 5
Care provider's effort to include me in decisions
4.5/ 5
Wait time at clinic
4.3/ 5
Care provider's concern for questions & worries
4.5/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
September 30, 2020
HUNTSMAN CANCER CENTER
Dr. Gupta is the best
UofU Patient
September 17, 2020
HUNTSMAN CANCER CENTER
Dr Gupta spent the time to discuss my situation.
UofU Patient
September 15, 2020
HUNTSMAN CANCER CENTER
Dr draw a pictorial about meditation advancements.
UofU Patient
September 01, 2020
HUNTSMAN CANCER CENTER
no sugar coating! lets deal with what we know, and here is our plan of attack. all said in a caring manner. made us feel like "we got this!"
UofU Patient
May 07, 2020
HUNTSMAN CANCER CENTER
none
UofU Patient
April 20, 2020
HUNTSMAN CANCER CENTER
I hoped I would receive more information about my. condition after my provider consulted with the expert at Huntsmans to read my CT scan, and that I would receive by USMail the results of my tests, as my provider promised.
UofU Patient
January 08, 2020
HUNTSMAN CANCER CENTER
NP Tinzen came in before Dr. Gupta to conduct the physical exam and explain lab test and scan results. She explained each segment thoroughly, asked questions, and made sure I understood. Her manner was professional and encouraging. Dr. Gupta consulted with NP Tinzen before coming in. She asked questions, listened, and objectively discussed wise treatment options for the immediate future and log term possibilities. Dr. Gupta included me in the decision making process for the next treatment option. She went further in evaluating and recommending diet and exercise routines in a motivating way that allowed me to see that my self-discipline would be as big a factor as any in fighting cancer return. So I am motivated to do my part and feel more hope.
UofU Patient
December 08, 2019
HUNTSMAN CANCER CENTER
excellent as always
UofU Patient
November 08, 2019
HUNTSMAN CANCER CENTER
Good
UofU Patient
October 28, 2019
HUNTSMAN CANCER CENTER
very good
UofU Patient
October 22, 2019
HUNTSMAN CANCER CENTER
Very insightful communication so that i could make good decisions
UofU Patient
October 16, 2019
HUNTSMAN CANCER CENTER
The care provider seemed in a hurry to leave for some reason. In the past it has not been that way
UofU Patient
October 04, 2019
HUNTSMAN CANCER CENTER
excellent
UofU Patient
August 21, 2019
HUNTSMAN CANCER CENTER
Tenzin preceded Dr. Gupta and was well versed in the 13 August lab results. She also was able to accurately answer questions from an analysis of a CT scan taken at another facility 2/2018. This thorough background research was not only impressive but crucial in determining the nature and growth of a lung tumor. Her physical examination was thorough as were her questions to determine if I properly understood the lab results. After she left, she debriefed Dr. Gupta, coordination which is efficient and made me confident. Dr. Gupta walked in informed and with a plan that provided astute continuity to my treatment. By way of background, Dr. Gupta's treatment plan included labs and scans to see if my prostate cancer returned and or metastasized after successful Lupron therapy. So far, so good on the prostate cancer but she noticed an area of concern on a lung scan. She ordered and studied the February 2018 CT Scan taken at another facility. The total of 3 CT scans indicate no growth but there is something there which may be another type of cancer. Dr. Gupta told me in this appointment session that she wanted to pool HCI resources by presenting to an "HCI Board" this week my information to find the best diagnosis and treatment. I am so grateful for this level of concern and proactivity! One could not ask for a better application and coordination of medical skills, expertise, and equipment. I thank God and Dr. Gupta!
UofU Patient
May 31, 2019
HUNTSMAN CANCER CENTER
Exemplary care in every respect!
UofU Patient
May 20, 2019
HUNTSMAN CANCER CENTER
Dr Gupta and her assistant who I know as Dave, have provided very professional medical services. They took the time to read my summary of prior treatments in Asheville NC. They had the previous biopsy and scan's summaries but were not content until they examined the tissue and scans with HCI expertise. This diligence resulted in the reinterpretation of my bone scan results from metastatic disease to degeneration in my upper sacrum. They confirmed this interpretation with their own scans on 13 May 2019. Such action was critical to treatment and of course to my quality of life! So grateful to Dr. Gupta and HCI!!
UofU Patient
April 15, 2019
HUNTSMAN CANCER CENTER
Dave I believe, was in residency (going soon to Inter Mountain Hospital in Riverton?) and Dr. Gupta had both read my synopsis of prior treatment in NC. They had also done their homework on my records including biopsy, bone scan, and CT scan. All this before I met them! So, seamless. First thing he addressed was the good news in the PSA test that had just taken place an hour before (amazing!) In both encounters, they had respect for my memo providing treatment history; my version of what my past Doctors had diagnosed and thought. They also did not hesitate to disagree, occasionally and tactfully, and to provide factual substantiation which I deeply appreciated. I was given a clear understanding of potential outcomes and treatment possibilities. I felt as if I was back in the cockpit as the pilot and they were my trusted copilot and flight engineer providing the information and professionalism necessary to keep my plane flying! They were outstanding!
UofU Patient
April 14, 2019
HUNTSMAN CANCER CENTER
I think she did okay since she was sick, but I didn't ask the questions I would have if she had been well.
UofU Patient
April 04, 2019
HUNTSMAN CANCER CENTER
I really liked our doctor. she was very kind and did not talk down to us. I felt well informed and believed that Mark was totally included in the conversation about the treatment plan.
UofU Patient
August 20, 2018
HUNTSMAN CANCER CENTER
my first time @ Huntsman. Went well !
UofU Patient
May 19, 2018
I do recommend people to go to huntsman and look into clinical trials. Everyone pays close attention to what I ask and say. Makes for the best respected care.
UofU Patient
April 11, 2018
couldn't have been any better
UofU Patient
April 10, 2018
We asked a lot of questions. She took the time to explain and answer.
UofU Patient
March 26, 2018
We were so pleased with our doctor's and every one who was involved in our visit. You made us feel like you care even though you had never met us before.
UofU Patient
March 24, 2018
ALL Very Good
UofU Patient
March 23, 2018
excellent
UofU Patient
March 15, 2018
Feel blessed to have such great people looking out for me.
UofU Patient
March 13, 2018
Very complete initial visit
UofU Patient
March 05, 2018
very good
UofU Patient
January 31, 2018
A class act!
UofU Patient
September 25, 2017
Dr. Gutma and Tenzen and the staff are amazing. I have the utmost faith and confidence in them.
UofU Patient
June 29, 2017
I was surprised how much time was spent in answering my questions I felt I was their only patient the way they took the time to answer my questions
UofU Patient
March 27, 2017
excellent review and care
UofU Patient
November 26, 2016
You are blessed to have so many loving, caring, concerned and supportive people. I'm blessed to have you working for me.
UofU Patient
September 06, 2016
It was a very comfortable experience and I felt very informed when I left there.
UofU Patient
May 21, 2016
somewhat difficult to understand. very clinical.
UofU Patient
April 26, 2016
My only concern with the provider is that I had a problem understanding her, but she was patient with me and repeated things until I thought I understood.
UofU Patient
April 23, 2016
Everyone very good at caring for me about all the above and that means all the providers. I also would recommend this hospital to all no mater where they come from.
UofU Patient
April 05, 2016
with no lab results available NO CONVERSATION took place about treatment!!!
UofU Patient
February 22, 2016
We are sorry to have to chose to receive chemo and radiation up in No Utah because of daily travel restrictions to and from the Ogden area to Huntsman because we feel we were in the best and most knowledgeable hands with Dr. Gupta and Voorhees and Sarah the nurse.
UofU Patient
December 09, 2015
The doctors and nursing staff are very great and good at what they do
UofU Patient
September 01, 2015
Dr Gupta takes plenty of time to explain and help you understand everything. So far, Dr Gupta & her team are excellent.
UofU Patient
August 24, 2015
Provider was very friendly and gave me the test results but his physical exam was very lacking.
UofU Patient
August 10, 2015
I felt that many of our questions were redirected and not answered. There was a lot of things going on and we were not sure what we were suppose to do and left not know what was next. I know I have a rare condition and not a lot is known, but we are new to the whole process and are not sure what we are to do next. The nurse has called and followed up some and explained some of the tests.
UofU Patient
August 05, 2015
Well informed to make use of anti nausea and antidiarrheal medications.
UofU Patient
July 19, 2015
Feel part of the decision making, making the process a little less overwhelming. Staff and doctor always helpful in explanations and showing their concern. Thank you
UofU Patient
June 17, 2015
Excellent. I have been treated like a person not like a number. I feel genuine concern from the care providers.
UofU Patient
June 15, 2015
Dr. Gupta has been extremely kind and helpful to us. We are really grateful for the way she describes things and answers our questions. Her explanations are clear and and the diagrams she draws are very clear and helpful.
UofU Patient
May 11, 2015
Have had cancer three times. This is the first experience with physicians and staff where all questions have been answered and I have felt cared about as an actual person.
UofU Patient
April 28, 2015
anyone who has a diagnosis of cancer needs to be seen and evaluated at Huntsman Cancer Hospital. They are the ultimate professionals with cancer care.
UofU Patient
April 02, 2015
We are very confident that Dr. Gupta and her staff are attuned to our needs and that they will provide us with excellent care.
UofU Patient
February 16, 2015
Not the best bedside manner in the world, but I had a guy on rotation come in first so that could be why. He was great, she was okay.
UofU Patient
February 16, 2015
Dr. Agarwal provided exceptional explanations of available treatment options.
UofU Patient
December 28, 2014
Thanks so much for all of your kind care ... I felt like I was in the very best of care the whole time.
UofU Patient
September 12, 2012
Dr. Gupta is the most outstanding medical provider I have ever seen in my life. She uncovered soooo many medical problems for me, and has me on the right track for care. I am so saddened she is going to Hunstman. I have never seen another physician who really listened to my problems, reviewed and made changes to my meds, and genuinely showed an interest in me. I had several issues and she took the time to address all of them. She is the very best!!!!!! It will be hard to fill her shoes. I hope you relay this message to her.
UofU Patient
September 11, 2012
Definitely would recommend Dr. Gupta but she is leaving for a fellowship at Huntsman.
UofU Patient
August 16, 2012
Dr Gupta spent very much quality time with me as a new patient. I had several complex problems, she listened and got me scheduled for appropriate tests. I feel extremely confident with her as my new primary care physician. I highly recommend her to all my friends. She is a rare find, professional, friendly, qualified.
UofU Patient
August 13, 2012
Appreciate the care I received at Centerville.
UofU Patient
August 06, 2012
I recommend Dr. Gupta to anyone I know who needs to find a doctor.
UofU Patient
August 03, 2012
I appreciate Dr. Gupta's thoroughness in examinations, always taking the time to explain everything, and her accessibility via My Chart.
UofU Patient
August 03, 2012
Dr. Gupta was very courteous and explained our medication and the purpose of each.
UofU Patient
July 25, 2012
Good
UofU Patient
July 18, 2012
Dr Gupta is the best I have ever experienced . I trust her completely . And I do recommend her too every one I know.
UofU Patient
July 02, 2012
I love Dr. Gupta!
UofU Patient
June 26, 2012
As with all doctors, this doctor always seems to be rushed, trying to get to all of her patients. Too many patients, not enough doctors.
UofU Patient
June 11, 2012
Dr. Gupta is a nice, competent physician. However I feel like she needs to take more time to explain things and to let me know what is going on. This is the one thing that could greatly improve my experience.
UofU Patient
May 01, 2012
Dr. Gupta is excellent. She is professional, very knowledgeable, she discusses everything carefully with the patient making sure she has a firm understanding of the patients problem. She is thorough in her treatment of the patient and her explanation of findings and treatments with the patient. My wife and I appreciate Dr. Gupta very much.
UofU Patient
March 30, 2012
We still don't know what's going on, so there wasn't really anything to explain. Again - fair = no opinion.
UofU Patient
March 29, 2012
Always good.
UofU Patient
March 27, 2012
Dr. Gupta is an excellent MD. I feel confident in her treatment and recommendations. I have referred friends to her.
UofU Patient
March 13, 2012
Dr. Gupta is very professional and a wonderful doctor. She has helped me to deal with the illness that I had, as well as work with me with my depression.
UofU Patient
March 08, 2012
I have recommended Dr. Gupta to several of my friends
UofU Patient
February 17, 2012
Dr. Gupta is the best doctor I have experienced any where .
UofU Patient
February 14, 2012
good
UofU Patient
January 26, 2012
I feel very confident in Dr Gupta. I recenly left another practice and came here. I am very happy with my decision to change.
UofU Patient
January 24, 2012
Only good experiences
UofU Patient
January 24, 2012
She is very uneducated on different diagnoses and how to treat them.
UofU Patient
January 10, 2012
I have always been impressed with Dr. Sumati Gupta! It seems she is genuinely interested in the welfare of her patients and takes the time necessary to provide whatever is needed for the patient.
UofU Patient
January 05, 2012
No careprovider knows everything. That is why Dr. Gupta refers to specialists in the U of U network. I appreciate those Doctors that have assisted in my care. We will continue to work with the U of Utah Medical Centers.
UofU Patient
January 04, 2012
Dr Gupta is always really generous with her time. She makes sure to listen to my concerns, and she takes enough time to explain everything thoroughly. I am very satisfied with the care she provides. She's a top tier doctor!
Sumati Gupta, MD, is an Assistant Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute.
Dr. Gupta is a specialist in adult medical oncology and her main areas of interest include Genitourinary Cancer (bladder, kidney, prostate and testicular cancer).
Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. She practiced at the University of Utah Clinics for 10 years in Primary Care and Geriatrics.
Dr. Gupta then completed fellowship in Medical Oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in Internal Medicine and Medical Oncology.
Dr. Gupta is a member of the Genitourinary Cancers program and the Genitourinary Malignancy Disease Oriented Team at the Huntsman Cancer Institute. She is a member of the American Society of Clinical Oncology. Dr. Gupta also does preclinical and clinical research at Huntsman Cancer Institute and her main areas of research interest are Epigenetics, Chemotherapy Resistance, Targeted therapy and Immunotherapy in the treatment of cancer.
Dr. Gupta is a clinical investigator and treats patients on clinical trials at Huntsman Cancer Institute. She also investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.
Dr. Gupta is also involved in individual and population-based studies to identify genetic and environmental risks of bladder cancer.
Dr. Gupta is a member of University of Utah’s Institutional Review Board. She also holds a part- time appointment at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and provides clinical expertise in Genitourinary Cancers.
Academic Locations
Huntsman Cancer Institute
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) |
Research Interests
- Mechanisms of Chemotherapy Resistance
- Immunotherapy
Education History
| Fellowship | University of Utah, Huntsman Cancer Institute Medical Oncology Fellow |
| Fellowship | Baylor College of Medicine Geriatric Medicine Fellow |
| Residency | Nassau University Medical Center Internal Medicine Resident |
| Professional Medical | Seth Gordhandas Sunderdas Medical College, Mumbai, India Medical School MD |
| Undergraduate | Atomic Energy Junior College High School Higher Secondary Certificate |
Selected Publications - Journal Articles
Journal Article
- Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K Pal (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma PMID: 32847703 DOI: 10.1016/j.eururo.2020.08.002 Yung Lyou et al. Eur Urol.2020. Eur Urol 2020 Aug 23;S0302-2838(20)30616-3.doi: 10.1016/j.eururo.2020.08.002. Online ahead of print. . Eur Urol, 20(S0302).
- Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer, 126(11), 2597-2606.
- Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK (2020). Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 38(16), 1797-1806.
- Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926.
- Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP (2019). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. (Epub ahead of print) Eur Urol Oncol.
- Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, ODonnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 125(4), 533-540.
- Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grunwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Mortazavi A, Vaughn DJ, Isaacs RE, Parker K, Chen X, Yu K, Porter D, Sharma S, Graus Porta D, Bajorin DF (2018). Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations.LID - CD-18-0229 [pii]LID - 10.1158/2159-8290.CD-18-0229 [doi]. (Epub ahead of print) Cancer Discov.
- Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. 124(10), 2115-2124.
- Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533.
- Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2017). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382.
- Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.LID - S1470-2045(18)30107-4 [pii]LID - 10.1016/S1470-2045(18)30107-4 [doi]. (Epub ahead of print) Lancet Oncol.
- Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
- Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Fam Cancer, 16(4), 545-550.
- Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602.
- Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
- Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
- Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
- Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis.
- Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs, 34(2), 243-52.
- Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
Editorial
Abstract
- Shilpa Gupta, Guru Sonpavde, Christopher J Weight, Bradley Alexander McGregor, Sumati Gupta, Benjamin Louis Maughan, Xiao X Wei, Ewan Gibb, Bharat Thyagarajan, David Johnson Einstein, Christopher B Dechet, William Thomas Lowrance, Paari J Murugan, Kerry L Kilbridge, Neeraj Agarwal, Elai Davicioni, Markus Eckstein, Matthew Mossanen, Mark A Preston, and Badrinath R Konety (2020). Pl Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. [Abstract]. 38(6_suppl), 439-439.
- Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, and Guru Sonpavde (6/2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. [Abstract]. 38(15_suppl), 5043-5043.
- Lesli Ann Kiedrowski, Roby Antony Thomas, Nicholas J Vogelzang, Guru Sonpavde, Sumati Gupta, Theodore Stewart Gourdin, Bishoy Morris Faltas, Rebecca Nagy, Richard B Lanman, and Petros Grivas (6/2020). FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC). [Abstract]. 38(6_suppl), 565-565.
- Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean H Hoffman-Censits, David I Quinn, Daniel Peter Petrylak, Matt D Galsky, Ulka N Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A Burris, Jessica Rearden, Yining Ye, Hao Wang, Susan Moran, Siamak Daneshmand, Dean F Bajorin, and Sumanta K Pal (06/2020). Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC). [Abstract]. 38(6_suppl), 576-576.
- Petros Grivas, Yohann Loriot, Susan Feyerabend, Rafael Morales-Barrera, Min Yuen Teo, Nicholas J Vogelzang, Enrique Grande, Yousef Zakharia, Nabil Adra, Ajjai Shivaram Alva, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Kenton Wride, Daleen Thomas, Rachel Dusek, Dale L Nepert, and Simon Chowdhury (06/2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. [Abstract]. 38(6_suppl), 440-440.
- Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, and Neeraj Agarwal (6/2020). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. [Abstract]. 38(6_suppl), 125-125.
- Benjamin Louis Maughan, Alejandro Sanchez, Brock B ONeil, William Thomas LowranceChristopher B Dechet, Danel Joseph Albertson, Deepika Sirohi, Sumati Gupta, Umang Swami, and Neeraj Agarwal (6/2020). A phase 1b/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AteoVax). [Abstract]. 38(6_suppl), TPS382-TPS382.
- Benjamin Louis Maughan, Roberto Nussenzveig, Umang Swami, Sumati Gupta, and Neeraj Agarwal (06/2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. [Abstract]. 38(6_suppl), TPS267-TPS267.
- Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, and Neeraj Agarwal (6/2020). Randomized phase II trial of radium-223 9RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. [Abstract]. 38(6_suppl), 125-125.
- Sergiusz Wesolowski Roberto Nussenzveig, Victor Sacristan Santos, John Esther, Divyam Goel, Umang Swami, Sumati Gupta, Benjamin Louis Maughan, Mark Yandell, Petros Grivas, and Neeraj Agarwal (6/2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). [Abstract]. 38(6_suppl), 570-570.
- A NecchiD Pouessel, R Leibowitz-Amit, A Flechon, S Gupta, P Barthelemy, M Maio, X Zhu, E Asatiani, G Serbest, H Zhen, Y Loriot (10/01/2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). [Abstract]. ESMO Annual Meeting 2018.
- Petros Grivas, Gregory Russell Pond, Rebecca J Nagy, Pedro C Barata, Prateek Mendiratta, Dharmesh Gopalakrishnan, Alexandra Drakaki, Sumati Gupta, Neeraj Agarwal, Jue Wang, Bishoy Faltas, Ulka N Vaishampayan, Gurudatta Naik, Bradley Alexander McGregor, Sumanta K Pal, Lesli Ann Kiedrowski, Richard B Lanman, Guru Sonpavde (06/01/2018). Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2018 [Abstract].
- Jacob Adashek, Sumanta K Pal, Vincent M Chung, Scott T Tagawa, Joel Picus, Hani M Babiker, Sumati Gupta, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benaim (2018). Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC). ASCO Annual Meeting 2018 [Abstract].
- Sumati Gupta, Andrew Butterfield, Timothy Parnell, Alexis Weston, Mohan Kaadige, Sunil Sharma (2018). Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners [Abstract]. Presented at Targeting DNA Methylation and Chromatin for Cancer Therapy in Atlanta March 2018.
- Ahmad Halwani, Zachary Burningham, Kelli M Rasmussen, Vikas Patil, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer (2017). Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration [Abstract]. ESMO Annual Meeting 2017.
- Sumanta Pal, Vincent Chun, Scott Tagawa, Joel Picus, Sumati Gupta, Julie Poore, Christine Peterson and Ely Benaim (2017). RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Metastatic Bladder Cancer [Abstract]. ESMO Annual Meeting 2017.
- Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, Gupta S, Rudin CM, Rosenberg JE, Kaufman DR, Schmidt EV, Grose M, Shafren D (2017). Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients [Abstract]. ASCO Annual Meeting 2017.
- Gong J, Chung VM, Picus J, Tagawa ST, Gupta S, Poore J, Peterson C, Benaim E, Pal SK (2017). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study. [Abstract]. ASCO Annual Meeting 2017.
- Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF, Robbins PB, Chism DD, Cho DC, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, di Pietro A, Rini BI (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. [Abstract]. ASCO Annual Meeting 2017.
- Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape [Abstract]. ASCO Annual Meeting 2017.
- Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer, Ahmad Halwani (2017). The role of academic affiliation in the treatment of metastatic castrate-resistant prostate cancer in the Veterans Health Administration Abstract- AVAHO 2017 [Abstract]. AVAHO 2017.
- Ahmad Halwani, Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C, Saier (2017). Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran’s Health Administration (VHA) AACR [Abstract]. Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting 2017.
- Gupta S, Albertson DJ, Parnell T, Dalley B, O Shea J, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal N (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC) [Abstract]. GU ASCO 2017.
- Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Milis SZ, Ali SM (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients [Abstract]. GU ASCO 2017.
- Hahn AW, Gill DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC) [Abstract]. GU ASCO 2017.
- Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy. [Abstract]. GU ASCO 2017.
- Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal N (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). [Abstract]. GU ASCO 2017.
- Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer [Abstract]. GU ASCO 2017.
- Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn, AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. GU ASCO 2017.
- Stenehjem D, Gupta S, Wade M, Gilcrease G, Garrido-Laguna I, Weis JR, Whisenant J, Sharma S (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Center for Investigational Therapeutics, Huntsman Cancer Institute, Salt Lake City, UT, USA, 2016.
- Agarwal N, Heemers H, Farnham JM, Patel SB, Gill D, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. 2016 ASCO.
- Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz AA, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urotheial carcinoma of the bladderÏ [Abstract]. ASCO Annual Meeting 2016.
- Gupta S (2016). A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes [Abstract]. ASCO 2015 Annual Meeting.
- Gupta S, Weston A, Bearrs J, Soldi R, Sharma S (2015). Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells [Abstract]. AACR Annual Meeting, April 2015.
- Gupta S (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis [Abstract]. Ren Fail, Jul;24(4), 461-6.
Other
- Nikita Pandya, Robert Hanlon, Andrew Butterfield, Sumati Gupta (2017). Epigenetics in Cancer: A Review. Can Stu The J 2017.
- Kharkar VJ, Ast A, Gupta S, Sharma S (2016). LSD2/KDM1B/AOF1 and Human Cancer Pathways: A Literature Review. Can Stu The J (1(1), pp. 1-5).
- Gupta S (2015). Epigenetics in Bladder Cancer. Focus on Phase I Newsletter.
Global Impact
Education History
| Professional Medical | Seth Gordhandas Sunderdas Medical College, Mumbai, India Medical School MD |
| Undergraduate | Atomic Energy Junior College High School Higher Secondary Certificate |